Silexion Therapeutics Corp
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Shareholders’ Equity (unaudited)
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
(U.S. dollars in thousands, except per share data)
| Ordinary shares · Additionalpaid-in Capital · Accumulated deficit · Total shareholders’ equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| BALANCE AT JANUARY 1, 2025 | 123,290 | *** | $2 | $39,263 | $(43,254) | $(3,989) |
| CHANGES DURING THE THREE MONTHS PERIOD ENDED MARCH 31, 2025 (unaudited): | ||||||
| Issuance of ordinary shares and warrants upon January Offering, net of issuance costs and exercise of pre-funded warrants to ordinary shares (see Note 4(a)) | 246,914 | 3 | 4,252 | 4,255 | ||
| Exercise of warrants upon January Offering (see Note 4(a)) | 42,683 | 1 | 863 | 864 | ||
| Issuance of ordinary shares and warrants upon January Inducement Offer, net of issuance costs (see Note 4(b)) | 148,102 | 2 | 2,812 | 2,814 | ||
| Share-based compensation | 21 | 21 | ||||
| Conversion of Underwriters Promissory Note | 18,519 | * | 356 | 356 | ||
| Net loss | (1,735) | (1,735) | ||||
| BALANCE AS OF MARCH 31, 2025 | 579,508 | *** | $8 | $47,567 | $(44,989) | $2,586 |
| BALANCE AT JANUARY 1, 2026 | 3,126,651 | $42 | $57,727 | $(55,166) | $2,603 | |
| CHANGES DURING THE THREE MONTHS PERIOD ENDED MARCH 31, 2026 (unaudited): | ||||||
| Share-based compensation | 204,134 | 3 | 342 | 345 | ||
| Issuance of Ordinary Shares under the At the Market Sales Agreement, net of issuance costs (see Note 6) | 64,080 | 1 | 75 | 76 | ||
| Net loss | (2,733) | (2,733) | ||||
| BALANCE AS OF MARCH 31, 2026 | 3,394,865 | $46 | $58,144 | $(57,899) | $291 | |
** All share amounts have been adjusted (in the case of prior periods, retroactively) to reflect a 1-for-15 reverse share splits effected in July 2025, as discussed in Note 1(e)
*** Net of 28 treasury shares held by the Company as of January 1, 2025 and March 31, 2025
F - 6
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.